Docket No. 143.006

1657 Itw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Abd Al-Roof Higazi

SERIAL NO.: 10/063,046

Group Art Unit: 1651

FILED:

May 8, 2002

Examiner: Barnhart, Lora E.

PLASMINOGEN FOR: PEPTIDE FOR REGULATION OF UROKINASE ACTIVATOR AND METHOD OF OPTIMIZING THERAPEUTIC EFFICACY

RESPONSE TO RESTRICTION REQUIREMENT & TO CORRECT DEFECT IN SEQUENCE FORMAT

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the outstanding Office Action mailed on August 27, 2004, Applicant files this response to Restriction Requirement under 35 U.S.C. 121, amends process claims 9 and 10, and submits a copy of the disk with attached paper copy of the Sequence Listing in accordance with 37 C.F.R. 1.181(c).

The Action required restriction to one of the following inventions under 35 U.S.C. 121:

Group I- Claims 1,2,7 and 8 drawn to a composition of an EEIIMI polypeptide and a fibrinolytic agent and method of enhancing the fibrinolytic activity of said agent, classified in class 424, subclass 94.64.

Group II- Claims 3 and 4, drawn to a composition of anti-LRP antibodies and a fibrinolytic agent, classified in class 424, subclass 131.1.

Group III- Claims 5 and 6, drawn to composition of LRP antagonist and a fibrinolytic agent, classified in class 424, subclass 185.1.

Group IV- Claims 9 and 10, drawn to a method of prolonging the half-life of a fibrinolytic agent using LRP antibodies, classified in class 435, subclass 188.5.

CERTIFICATE OF Express Mail Service under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service by Express Mail No. ED 096541040 US on September 21, 2004 addressed to: Commissioner for Patents, Washington, D.C. 20231.

BY Kashide A Kamah

Date: